Clindamycin

C. diff Risk

High

Oral Bioavailability

Excellent

Approximate Cost

IV: $$$
PO: $

Dosing

300-450mg IV q8h for usual indications

900mg IV q8h for necrotizing skin/soft tissue infections or toxic shock syndrome

300-450mg PO q6h

CrCl >50 mL/min

  • 600 - 900 mg IV Q8h

  • 300 - 450 mg PO Q8hCrCl <50 mL/min

  • No change

Consider dose reduction in hepatic insufficiency

Creatinine Clearance >50mL/min/1.73m²Creatinine Clearance 10-50mL/min/1.73m²Creatinine Clearance ≤10mL/min/1.73m²Intravenous
10mg/kg/dose IV Q8H
Maximum: 900mg/dose

Oral
10mg/kg/dose PO Q8H
Consider dividing doses over 450mg/doseNo changeNo change

Creatinine Clearance >50mL/min/1.73m²Intravenous
13mg/kg/dose IV Q8H
Maximum: 900mg/dose

Oral
13mg/kg/dose PO Q8H
Consider dividing doses over 450mg/dose

Consider dose reduction in hepatic insufficiency

General Information

  • Diarrhea

  • C. difficile

Laboratory

  • Not routinely indicated

Clinical

  • Hypersensitivity

  • GI effects

  • Photosensitivity

  •  Muscle relaxants, e.g., atracurium, baclofen, diazepam.

  •  St. Johns Wort

Antimicrobial class: Lincosamide

Pregnancy category: B

Average serum half life: 2.4 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor

Anaerobic infections above the diaphragm, especially dental infection.

Gram positive skin and soft tissue infections including necrotizing fasciitis as an adjunctive agent to a beta-lactam for reducing toxin production.

Skin & soft tissue infections involving susceptible MRSA.

Susceptible infections and surgical prophylaxis in setting of IgE mediated beta-lactam allergy.

For decreasing toxin production in toxic shock syndrome.